PMID- 23427945
OWN - NLM
STAT- MEDLINE
DCOM- 20130703
LR  - 20181202
IS  - 1744-7593 (Electronic)
IS  - 1742-5247 (Linking)
VI  - 10
IP  - 5
DP  - 2013 May
TI  - Nanopharmaceuticals to target antifilarials: a comprehensive review.
PG  - 665-78
LID - 10.1517/17425247.2013.771630 [doi]
AB  - INTRODUCTION: Currently emphasized conventional chemotherapies for the 
      elimination of lymphatic filariasis (LF) are imperfect due to unfocused targeting 
      of poorly water-soluble antifilarial drugs. The profound location of drug targets 
      (filarial parasites or wolbachia) within the complex anatomy of lymphatic tissues 
      often necessitates prolonged treatment schedules with high doses leading to 
      undesired side effects and poor patient compliance. Therefore, we need to 
      reformulate antifilarial drugs taking the advantages of nanotechnology through a 
      wide range of nanomedical carriers, which improve drug efficacy, increase 
      bioavailability, and diminish toxicity. AREAS COVERED: Connotations of drug 
      delivery systems (DDSs) to target lymphatic filaroids or wolbachia and systemic 
      microfilaria have been discussed. The potentials of liposomes and solid lipid 
      nanoparticles for the treatment of LF are highlighted. Various critical factors, 
      viz optimal size range, surface properties, preferred pH, mechanism of 
      reticuloendothelial avoidance, and control of the release of antifilarial agents 
      for safe elimination of parasites, are enclosed to design a novel DDS for LF. The 
      review of nanotechnological approaches to improve antifilarial chemotherapy will 
      help to resolve existing technological gaps. EXPERT OPINION: Precincts in the 
      antifilarial discovery programs can never be overcome by conventional methods. 
      Nanomedicine encompasses wide-range solution for each single problem (i.e., from 
      poor solubility to nonspecific targeting of antifilarial agents) for the cure of 
      LF at low costs and may reduce the economic burden of LF diseases. Advances in 
      nanotechnology loom will certainly come forward as silver bullets in the near 
      future for quick diagnosis, control, and elimination of this tropically neglected 
      disease.
FAU - Ali, Mohammad
AU  - Ali M
AD  - Hamdard University (Jamia Hamdard), Hamdard Nanobiotechnology Center for Advance 
      Research, Nanomedicine Lab, Faculty of Engineering & Interdisciplinary Sciences, 
      New Delhi-110062, India. mohd.ali.hamdard@gmail.com
FAU - Afzal, Mohammad
AU  - Afzal M
FAU - Bhattacharya, Shailja Misra
AU  - Bhattacharya SM
FAU - Ahmad, Farhan Jalees
AU  - Ahmad FJ
FAU - Dinda, Amit Kumar
AU  - Dinda AK
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130222
PL  - England
TA  - Expert Opin Drug Deliv
JT  - Expert opinion on drug delivery
JID - 101228421
RN  - 0 (Filaricides)
RN  - 0 (Liposomes)
SB  - IM
MH  - Animals
MH  - Chemistry, Pharmaceutical
MH  - *Drug Delivery Systems
MH  - Elephantiasis, Filarial/*drug therapy
MH  - Filaricides/*administration & dosage
MH  - Filarioidea/drug effects
MH  - Humans
MH  - Liposomes/*chemistry
MH  - Nanoparticles/*chemistry
MH  - Wolbachia/drug effects
EDAT- 2013/02/23 06:00
MHDA- 2013/07/05 06:00
CRDT- 2013/02/23 06:00
PHST- 2013/02/23 06:00 [entrez]
PHST- 2013/02/23 06:00 [pubmed]
PHST- 2013/07/05 06:00 [medline]
AID - 10.1517/17425247.2013.771630 [doi]
PST - ppublish
SO  - Expert Opin Drug Deliv. 2013 May;10(5):665-78. doi: 10.1517/17425247.2013.771630. 
      Epub 2013 Feb 22.